Schonfeld Strategic Advisors LLC Has $969,000 Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Schonfeld Strategic Advisors LLC raised its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 277.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 21,770 shares of the company's stock after purchasing an additional 16,003 shares during the quarter. Schonfeld Strategic Advisors LLC's holdings in Omnicell were worth $969,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of OMCL. Smartleaf Asset Management LLC grew its position in shares of Omnicell by 51.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock valued at $35,000 after buying an additional 273 shares during the last quarter. Johnson Financial Group Inc. acquired a new stake in Omnicell in the 4th quarter valued at approximately $37,000. Van ECK Associates Corp boosted its position in Omnicell by 47.0% during the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after acquiring an additional 315 shares during the period. Headlands Technologies LLC acquired a new position in shares of Omnicell during the fourth quarter valued at $53,000. Finally, First Horizon Advisors Inc. lifted its holdings in Omnicell by 36.3% in the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock worth $59,000 after purchasing an additional 355 shares during the period. Institutional investors and hedge funds own 97.70% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on OMCL. JPMorgan Chase & Co. reduced their price target on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research note on Thursday, March 20th. Benchmark cut their target price on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. StockNews.com cut Omnicell from a "buy" rating to a "hold" rating in a research note on Saturday, May 3rd. Finally, Wells Fargo & Company cut their target price on shares of Omnicell from $38.00 to $31.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 7th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $45.83.

Omnicell Stock Up 6.5%

Shares of OMCL traded up $1.68 during mid-day trading on Monday, hitting $27.46. 1,006,253 shares of the company's stock were exchanged, compared to its average volume of 553,497. The firm has a fifty day moving average of $32.28 and a two-hundred day moving average of $39.97. Omnicell, Inc. has a twelve month low of $22.66 and a twelve month high of $55.75. The stock has a market cap of $1.29 billion, a price-to-earnings ratio of 101.71, a P/E/G ratio of 7.53 and a beta of 0.78. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.10. The business had revenue of $269.67 million during the quarter, compared to the consensus estimate of $260.18 million. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Omnicell's quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.03 EPS. On average, sell-side analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.